Chaitanya R Divgi

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
  2. ncbi request reprint Instant gratification must wait
    Chaitanya Divgi
    Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA 19104, USA
    Eur J Nucl Med Mol Imaging 33:979-80. 2006
  3. doi request reprint The use of positron-emission tomography in the diagnosis of tumour phenotype
    Chaitanya Divgi
    University of Pennsylvania, Philadelphia, PA 19104, USA
    BJU Int 101:36-8. 2008
  4. pmc Molecular imaging of pulmonary cancer and inflammation
    Chaitanya R Divgi
    Nuclear Medicine Clinical Molecular Imaging, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Proc Am Thorac Soc 6:464-8. 2009
  5. pmc Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 49:1066-74. 2008
  6. pmc 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1878-85. 2011
  7. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
  8. ncbi request reprint Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2707-13. 2007
  9. pmc (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
  10. doi request reprint Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250
    Daniel A Pryma
    Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Nucl Med 52:535-40. 2011

Detail Information

Publications47

  1. ncbi request reprint Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
    ..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
  2. ncbi request reprint Instant gratification must wait
    Chaitanya Divgi
    Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA 19104, USA
    Eur J Nucl Med Mol Imaging 33:979-80. 2006
  3. doi request reprint The use of positron-emission tomography in the diagnosis of tumour phenotype
    Chaitanya Divgi
    University of Pennsylvania, Philadelphia, PA 19104, USA
    BJU Int 101:36-8. 2008
  4. pmc Molecular imaging of pulmonary cancer and inflammation
    Chaitanya R Divgi
    Nuclear Medicine Clinical Molecular Imaging, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Proc Am Thorac Soc 6:464-8. 2009
    ..PET and SPECT imaging with other radiotracers of interest will also be reviewed. Future directions in PET imaging of pulmonary pathophysiology will also be explored...
  5. pmc Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 49:1066-74. 2008
    ..An analysis was performed to assess lesion detectability by (111)In-J591 gamma-camera imaging compared with standard imaging methods and the effect of increasing antibody mass on lesion detectability, biodistribution, and dosimetry...
  6. pmc 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1878-85. 2011
    ..The primary aim of this analysis was to examine the quantitative features of antibody-antigen interactions in tumors and normal tissue after parenteral administration of antitumor antibodies to human patients...
  7. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  8. ncbi request reprint Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2707-13. 2007
    ..This phase I trial tested the hypothesis that J591 could be used as a vascular targeting platform for patients with nonprostate solid tumors...
  9. pmc (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
    ..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)...
  10. doi request reprint Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250
    Daniel A Pryma
    Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Nucl Med 52:535-40. 2011
    ....
  11. ncbi request reprint Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7454-61. 2005
    ..The relationship among dose, safety, pharmacokinetics, and antibody-dependent cellular cytotoxicity (ADCC) activation for unlabeled J591 has not been explored...
  12. pmc Bone marrow dosimetry using 124I-PET
    Jazmin Schwartz
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Nucl Med 53:615-21. 2012
    ....
  13. ncbi request reprint Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer
    Chaitanya R Divgi
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1412-21. 2004
    ..This trial was performed to determine the maximum tolerated whole-body radiation-absorbed dose of fractionated (131)I-cG250...
  14. ncbi request reprint Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2528-34. 2007
    ..The blood-brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenous radioimmunotherapy using anti-CD20 antibody can be delivered to PCNSL...
  15. pmc Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin
    Ann Marie Chacko
    Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    J Nucl Med 55:500-7. 2014
    ....
  16. ncbi request reprint Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer
    Christine A Ciunci
    Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    Cancer 120:77-85. 2014
    ..Therefore, a phase 1/pharmacodynamic trial of everolimus with cetuximab was performed...
  17. doi request reprint Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial
    Chaitanya R Divgi
    Columbia University, New York, NY 10032, USA
    J Clin Oncol 31:187-94. 2013
    ..A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken...
  18. doi request reprint Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agent
    Andrew B Newberg
    Department of Radiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nucl Med Commun 30:314-8. 2009
    ..The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously...
  19. pmc Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma
    Cameron J Koch
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Eur J Nucl Med Mol Imaging 37:2048-59. 2010
    ....
  20. doi request reprint Molecular imaging of renal cell carcinoma
    Rodolfo Perini
    Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19105, USA
    Urol Clin North Am 35:605-11; vi. 2008
    ..This article discusses the evolving role of molecular imaging in the evaluation of renal cancer, including current and future applications...
  21. doi request reprint A review of contemporary data on surgically resected renal masses--benign or malignant?
    Anthony T Corcoran
    Division of Urology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Urology 81:707-13. 2013
    ..To clearly define the proportions of benign vs malignant histologic findings in resected renal masses through an in-depth review of the contemporary medical data to assist in preoperative risk assessment...
  22. pmc Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  23. pmc Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    EJNMMI Res 3:42. 2013
    ....
  24. ncbi request reprint Radiopharmaceutical chemistry with iodine-124: a non-standard radiohalogen for positron emission tomography
    Ann Marie Chacko
    Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
    Med Chem 7:395-412. 2011
    ..The review will conclude by highlighting promising future directions in using (124)I as a positron emitter in PET radiochemistry and molecular imaging...
  25. ncbi request reprint I-123 MIBG scan of metastatic neuroblastoma mimicking a bone scan
    Gregory Ravizzini
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Nucl Med 31:558-60. 2006
  26. ncbi request reprint Radiopharmaceutical therapy for palliation of bone pain from osseous metastases
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1358-65. 2004
    ..This article illustrates the salient features of these radiopharmaceuticals, including the approved dose, method of administration, and indications for use. We conclude with recommended guidelines for therapy and follow-up...
  27. ncbi request reprint New strategies in radioimmunotherapy for lymphoma
    Neeta Pandit-Taskar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 5:364-71. 2003
    ..This review highlights features of radioimmunotherapy that are relevant to non-Hodgkin's lymphoma, focusing on the two anti-CD20 antibodies...
  28. ncbi request reprint Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients
    Neeta Pandit-Taskar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:1202-8. 2006
    ..The study also projected the radiation-absorbed dose to the fetus from LSG for SLN mapping...
  29. doi request reprint Non-invasive assessment of tumor neovasculature: techniques and clinical applications
    Rodolfo Perini
    Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Metastasis Rev 27:615-30. 2008
    ....
  30. ncbi request reprint Imaging: staging and evaluation of lymphoma using nuclear medicine
    Chaitanya Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 32:S11-8. 2005
    ..This article examines the role of the different imaging techniques available and the use of these techniques in the staging and evaluation of patients with Hodgkin's and non-Hodgkin's lymphoma...
  31. ncbi request reprint Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination
    Howard L Kaufman
    Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Clin Cancer Res 11:6757-62. 2005
  32. ncbi request reprint Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism
    Olga T Hardy
    Division of Endocrinology, The Children s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    J Clin Endocrinol Metab 92:4706-11. 2007
    ..This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs. diffuse disease and identifying the location of focal lesions...
  33. ncbi request reprint Current status of therapy of solid tumors
    Yuliya S Jhanwar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:141S-50S. 2005
    ..This review will describe seminal studies that have paved the way to an understanding of radioimmunotherapy in solid tumors. Finally, the authors' views of the future of this promising cancer therapy will be presented...
  34. ncbi request reprint Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy
    Joseph A O'Donoghue
    Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Biother Radiopharm 17:435-43. 2002
    ..Treatment may be prescribed on the basis of administered activity or absorbed dose. An optimal definition of maximum tolerated dose will enable the clinical benefits of RIT to be maximized...
  35. ncbi request reprint Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response
    George Sgouros
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:260-8. 2003
    ....
  36. ncbi request reprint Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  37. ncbi request reprint Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Health Phys 92:33-9. 2007
    ....
  38. ncbi request reprint Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
    J Thorac Oncol 2:947-52. 2007
    ..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies...
  39. doi request reprint Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:33-9. 2010
    ..A prospective clinical study was designed to explore this hypothesis. Patients and..
  40. ncbi request reprint Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
    Curr Oncol Rep 6:222-9. 2004
    ..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development...
  41. ncbi request reprint A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States
    Michael K Schultz
    The National Institute of Standards and Technology, Nuclear Medicine Standards Program, 100 Bureau Drive, MS 8462, Gaithersburg, MD 20899, USA
    Appl Radiat Isot 66:252-60. 2008
    ..All results were within US Nuclear Regulatory Commission conformance limits (+/-20%) for defining therapeutic misadministrations...
  42. ncbi request reprint PET: too much of a good thing? Does the plethora of choices impact on patient management?
    Chaitanya Divgi
    Eur J Nucl Med Mol Imaging 32:398. 2005
  43. ncbi request reprint Editorial: what ails solid tumor radioimmunotherapy?
    Chaitanya Divgi
    Cancer Biother Radiopharm 21:81-4. 2006
  44. ncbi request reprint Active and passive immunotherapy: vaccines and antibodies
    Egbert Oosterwijk
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    BJU Int 99:1301-4. 2007
  45. doi request reprint Radioiodine imaging and treatment in thyroid disorders
    Wei Shen Griggs
    Fairfax Radiological Consultants, Fairfax, VA 22031, USA
    Neuroimaging Clin N Am 18:505-15, viii. 2008
    ..Iodine uptake also permits treatment, using I-131, of hyperthyroid disease and cancer, for which I-131 is the primary treatment...
  46. ncbi request reprint Action plan for emerging molecular imaging technologies
    Alexander J McEwan
    J Nucl Med 49:37N-40N. 2008
  47. ncbi request reprint A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:1482-8. 2002
    ..During this same time period, other patients at our center were prepared for RRA by hormone withdrawal...